Market Overview

UPDATE: Jefferies Downgrades Cree to Underperform on Near-Term Outlook

Share:
Related CREE
Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher
Benzinga's Volume Movers
Is Google Fiber Set to Venture into North Carolina Next? - Analyst Blog (Zacks)

Jefferies downgraded Cree (NASDAQ: CREE) from Buy to Underperform.

Jefferies commented, "We see Cree as well positioned to benefit from one of the strongest secular growth stories in Clean Tech, however we believe the Street is overly optimistic about revenue growth in FY2013 and see limited catalysts in the coming quarters to lead to improving multiples or increasing estimates. We advise investors to reduce exposure to the name in the next few quarters given: 1) Weak near-term market conditions and 2) Recent share appreciation."

Cree closed at $32.61 on Wednesday.

Latest Ratings for CREE

DateFirmActionFromTo
Oct 2014Bank of AmericaUpgradesUnderperformNeutral
Oct 2014Bank of AmericaMaintainsUnderperform
Oct 2014Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for CREE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CREE)

Around the Web, We're Loving...

Get Benzinga's Newsletters